Home/ Blog/ Understanding Breast Cancer Subtypes

Understanding Breast Cancer Subtypes: How Molecular Testing Helps Guide Treatment

Pathologist examining a slide under a microscope in a laboratory

A breast cancer diagnosis can bring many questions. Patients may hear terms such as ER-positive, PR-positive, HER2-positive, HER2-negative, triple-negative, luminal A, luminal B, Ki-67 and molecular testing during conversations with their doctor or while reading a pathology report.

These terms can initially sound complicated, but they all relate to an important concept: breast cancer is not one single disease.

Different breast cancers can have different biological characteristics. Those characteristics can influence how a tumour behaves and which treatments may be appropriate.

This is why modern breast cancer diagnosis goes beyond simply answering the question, “Is this cancer?”

Doctors may also need to understand:

  • What type of breast cancer is present?
  • What is the tumour grade?
  • What is the stage?
  • Does the tumour have estrogen receptors?
  • Does it have progesterone receptors?
  • Is HER2 present?
  • How actively are the tumour cells dividing?
  • Are additional molecular tests appropriate?
  • Could the results influence treatment?

The National Cancer Institute explains that breast cancer cells are commonly tested for estrogen receptor (ER), progesterone receptor (PR) and HER2, while other biomarkers such as Ki-67 may also provide clinically useful information.

Understanding these tests can help patients make sense of their pathology reports and understand why their oncology team may recommend specific treatment approaches.

What Are Breast Cancer Subtypes?

Breast cancer can be classified in different ways.

Doctors may describe a tumour based on:

  • Histological type
  • Grade
  • Stage
  • Hormone receptor status
  • HER2 status
  • Molecular characteristics
  • Other biomarkers

When people talk about breast cancer molecular subtypes, they are generally referring to groups of tumours that share certain biological characteristics.

Commonly discussed groups include:

  • Luminal A
  • Luminal B
  • HER2-enriched
  • Basal-like or triple-negative breast cancer

In everyday clinical practice, doctors may also describe breast cancers using combinations such as:

  • Hormone receptor-positive / HER2-negative
  • Hormone receptor-positive / HER2-positive
  • Hormone receptor-negative / HER2-positive
  • Triple-negative breast cancer

These classifications are useful because they provide information about tumour biology and can contribute to treatment planning.

Why Is Breast Cancer Subtyping Important?

Two people can both have breast cancer but require very different treatment strategies.

For example, one tumour may depend on hormone signalling, while another may have increased HER2 activity. Another tumour may not express ER, PR or HER2 at all.

These differences can influence whether treatments such as:

  • Hormone therapy
  • Chemotherapy
  • HER2-targeted therapy
  • Immunotherapy
  • Other targeted therapies

may be appropriate.

However, biomarker results do not determine treatment by themselves. Doctors also consider tumour stage, grade, size, lymph-node involvement, overall health, previous treatment and other clinical information.

What Are ER and PR?

ER stands for estrogen receptor.

PR stands for progesterone receptor.

These are receptors found on cells that can respond to hormones.

Some breast cancer cells contain estrogen and/or progesterone receptors.

When breast cancer cells contain estrogen receptors, the cancer is generally described as ER-positive.

When they contain progesterone receptors, it may be described as PR-positive.

A tumour can therefore have different combinations of ER and PR results. For example:

  • ER-positive / PR-positive
  • ER-positive / PR-negative
  • ER-negative / PR-positive
  • ER-negative / PR-negative

The results help doctors understand the biology of the tumour.

What Does ER-Positive Breast Cancer Mean?

ER-positive breast cancer means that the cancer cells have estrogen receptors.

This is clinically important because hormone signalling can contribute to the growth of hormone receptor-positive breast cancers. For appropriate patients, hormone-based treatment may therefore form an important part of treatment planning.

The National Cancer Institute explains that testing for estrogen and progesterone receptors can help determine whether hormone therapy may be useful.

However, an ER-positive result does not provide the complete treatment plan. Doctors also need to consider:

  • Tumour stage
  • Tumour grade
  • HER2 status
  • Lymph-node involvement
  • Other pathological characteristics
  • Patient health
  • Previous treatment

What Does PR-Positive Breast Cancer Mean?

PR-positive means that progesterone receptors have been detected in the tumour cells.

PR results are usually considered alongside ER results.

For example, a cancer that is both ER-positive and PR-positive has a different biological profile from a cancer that is ER-positive but PR-negative. This information can contribute to the overall classification of the tumour.

What Is HER2?

HER2 stands for human epidermal growth factor receptor 2.

HER2 is a protein involved in cell growth and signalling.

Some breast cancers have increased HER2 expression or other HER2-related abnormalities. These cancers may be classified as HER2-positive breast cancer.

HER2 testing is therefore an important component of breast cancer pathology.

What Does HER2-Positive Breast Cancer Mean?

A HER2-positive breast cancer has characteristics indicating increased HER2 activity according to established testing criteria.

HER2 status can have major treatment implications because HER2-targeted therapies are available for appropriate patients. This is an example of how molecular or biomarker testing can contribute directly to personalised cancer treatment.

Instead of treating every breast cancer in exactly the same way, doctors can use tumour biology to help determine which therapies are most appropriate.

Why Is HER2 Testing Done?

HER2 testing helps doctors determine whether a tumour has HER2-related characteristics that could make HER2-directed treatment relevant.

The testing may be performed using laboratory techniques such as:

  • Immunohistochemistry
  • In situ hybridisation in appropriate cases

The exact testing approach depends on the pathology situation and established clinical protocols. The NCI identifies HER2 testing as one of the key biomarker evaluations used in breast cancer.

What Is Triple-Negative Breast Cancer?

Triple-negative breast cancer, commonly abbreviated as TNBC, is generally defined by the absence of:

  • Estrogen receptors
  • Progesterone receptors
  • HER2

In other words:

ER-negative + PR-negative + HER2-negative = Triple-negative breast cancer

This classification is important because hormone-based therapies and HER2-targeted therapies that are used for certain other breast cancers are not applicable in the same way to triple-negative disease. Treatment therefore requires a different clinical approach.

The NCI specifically defines triple-negative breast cancer based on the absence of ER, PR and HER2.

Is Triple-Negative Breast Cancer More Aggressive?

Triple-negative breast cancers can have different biological and clinical behaviour from hormone receptor-positive breast cancers. They may grow and spread more rapidly in some patients and have historically had fewer targeted treatment options.

However, treatment options for triple-negative breast cancer have expanded. Depending on the individual case, treatment may involve combinations of:

  • Surgery
  • Chemotherapy
  • Immunotherapy
  • Radiation
  • Other systemic treatments

Treatment should always be determined by the oncology team based on the specific cancer.

What Is Luminal A Breast Cancer?

Luminal A is one of the commonly discussed molecular subtypes. It is generally associated with characteristics such as:

  • ER-positive status
  • PR-positive status
  • HER2-negative status
  • Lower proliferation
  • Often lower tumour grade

Ki-67 may also be relatively low.

Luminal A cancers often have a different biological behaviour from cancers with higher proliferation. However, classification is not based on one laboratory result. Doctors consider the complete pathology and clinical picture.

What Is Luminal B Breast Cancer?

Luminal B breast cancers are generally hormone receptor-positive but may show characteristics associated with higher proliferation. They may be:

  • HER2-negative or HER2-positive
  • Associated with higher Ki-67
  • PR-positive or PR-negative

Compared with luminal A tumours, luminal B cancers may have biological characteristics associated with greater tumour proliferation. This distinction can contribute to treatment planning.

What Is HER2-Enriched Breast Cancer?

HER2-enriched is a molecular subtype associated strongly with HER2 biology.

However, molecular classification and routine clinical HER2 testing are not necessarily identical concepts. A patient’s pathology report may simply describe HER2 status based on clinical testing. The treating team interprets the result together with hormone receptor status and other tumour characteristics.

What Is Ki-67?

Ki-67 is a protein associated with cell proliferation.

In simple terms, it can provide information about how actively tumour cells are dividing. A higher Ki-67 level can indicate a greater proportion of actively proliferating cells.

However, Ki-67 should not be treated as a standalone measure of prognosis or treatment response. The National Cancer Institute notes that Ki-67 testing may provide information relevant to treatment decisions, but its interpretation needs to be considered alongside other tumour characteristics.

How Is Breast Cancer Molecular Testing Performed?

Biomarker testing is generally performed on tissue containing cancer cells. The tissue may be obtained through:

  • Core needle biopsy
  • Other types of biopsy
  • Surgical removal of the tumour
  • Tissue obtained during surgery

The tissue is processed in a pathology laboratory. Pathologists and laboratory professionals then use appropriate techniques to evaluate the relevant markers.

The NCI explains that biomarker testing for breast cancer is generally performed using tissue obtained during biopsy or surgery.

What Is Immunohistochemistry?

Immunohistochemistry, often abbreviated as IHC, is a laboratory technique used to identify specific proteins within tissue. It uses antibodies that bind to particular proteins.

IHC can be used in breast cancer testing to assess markers such as:

  • ER
  • PR
  • HER2
  • Ki-67

The resulting staining pattern and intensity are interpreted according to established criteria. This information becomes part of the pathology assessment.

What Is Molecular Testing?

Molecular testing refers more broadly to laboratory techniques that examine biological characteristics at the molecular level.

Depending on the cancer and clinical question, molecular testing can investigate:

  • DNA
  • RNA
  • Gene expression
  • Gene alterations
  • Protein expression
  • Other molecular characteristics

Not every breast cancer patient requires extensive molecular testing. Testing should be selected according to the clinical question. At TruScan, this kind of work sits with molecular biology services when a doctor has recommended a specific test.

Is Molecular Testing the Same as Genetic Testing?

No.

This is one of the most important distinctions for patients to understand.

Tumour Biomarker Testing

This examines characteristics of the cancer cells. Examples include:

  • ER
  • PR
  • HER2
  • Ki-67

Inherited Genetic Testing

This looks for genetic variants that may be inherited and potentially passed through families. Examples can include genes such as:

  • BRCA1
  • BRCA2
  • Other hereditary cancer-associated genes

A person can therefore have:

  • ER-positive breast cancer without having an inherited BRCA mutation.
  • An inherited genetic risk even before developing cancer.

These tests answer different clinical questions.

Why Does Molecular Testing Matter in Precision Medicine?

Traditional cancer treatment often relied heavily on tumour location and histological appearance. Modern oncology increasingly combines this information with molecular and biomarker information. This approach is often described as precision medicine.

The objective is to understand the individual tumour and identify treatments that are more likely to be useful. For breast cancer, this may mean using ER, PR, HER2 and other biomarkers to guide decisions.

The NCI describes biomarker testing as an important component of precision medicine because biomarkers can help doctors select treatments that may be more appropriate for particular cancers.

Can Breast Cancer Biomarkers Change?

Yes. Cancer is biologically dynamic.

The characteristics of a tumour at the time of the original diagnosis may not always be identical to those of cancer that returns later. For example, hormone receptor status can sometimes change between the original tumour and recurrent disease.

The NCI notes that hormone receptor status may change when breast cancer recurs. Because of this, doctors may sometimes recommend a new biopsy and repeat biomarker testing when cancer returns.

Why Is Pathology Important in Breast Cancer?

Pathology provides the foundation for understanding what type of tumour is present.

A pathology report can contain information about:

  • Histological tumour type
  • Tumour grade
  • Tumour size
  • Lymphovascular involvement
  • Surgical margins
  • Lymph-node findings
  • ER
  • PR
  • HER2
  • Ki-67
  • Other relevant pathological features

These findings help the oncology team develop an appropriate treatment strategy. Pathology is therefore much more than simply confirming that cancer exists. It helps describe what kind of cancer it is. TruScan’s pathology service is the laboratory setting in which this kind of tissue and biomarker assessment is carried out when the required test is available.

Grade vs Stage vs Molecular Subtype

These three concepts are often confused.

What Is Cancer Stage?

Stage describes the extent of cancer in the body. It can include information about:

  • Primary tumour size
  • Lymph nodes
  • Spread to distant organs

What Is Cancer Grade?

Grade describes characteristics of the cancer cells and how abnormal they appear under microscopic examination. It can provide information about how aggressively the tumour may behave.

What Is Molecular Subtype?

Molecular or biomarker classification describes biological characteristics such as:

  • ER
  • PR
  • HER2
  • Ki-67
  • Other molecular markers

All three can provide different and complementary information.

How Can Biomarker Testing Influence Treatment?

Biomarker testing can help doctors determine whether particular treatment strategies may be relevant. For example:

Hormone Receptor-Positive Breast Cancer

Hormone therapy may be an important component of treatment for appropriate patients.

HER2-Positive Breast Cancer

HER2-targeted treatment may be considered when clinically appropriate.

Triple-Negative Breast Cancer

Treatment may involve chemotherapy, immunotherapy and/or other approaches depending on the specific situation.

Higher-Proliferation Tumours

Additional characteristics may influence decisions about systemic therapy.

The treatment plan is never determined by a single marker alone.

What Happens After Molecular Testing?

Once pathology and biomarker results are available, the treating team reviews them alongside:

  • Imaging
  • Cancer stage
  • Tumour grade
  • Lymph-node status
  • Patient age
  • General health
  • Menopausal status where relevant
  • Previous treatment
  • Family history
  • Other laboratory findings

The oncologist may then recommend an appropriate treatment strategy. Depending on the case, this may involve:

  • Surgery
  • Chemotherapy
  • Radiation
  • Hormone therapy
  • Targeted therapy
  • Immunotherapy
  • A combination of treatments
  • Active surveillance in selected circumstances

What Is the Role of TruScan Diagnostics in Breast Cancer Testing?

TruScan Diagnostics is relevant to the laboratory and diagnostic component of breast cancer evaluation. The services that align with this topic are pathology, molecular biology and cancer screening.

A typical pathway may involve:

Clinical consultation → Imaging → Biopsy → Pathology → Biomarker testing → Molecular testing where appropriate → Oncology consultation → Treatment planning

Pathology helps establish the characteristics of the tumour.

Biomarker testing can provide information about ER, PR and HER2.

Additional molecular testing may be considered when there is a specific clinical reason.

Cancer screening, meanwhile, belongs primarily to the earlier detection and preventive side of healthcare.

Patients should confirm with TruScan whether the specific pathology or molecular test recommended by their doctor is currently available.

Breast Cancer Screening vs Diagnostic Testing

These are two different concepts.

Screening

Screening is intended to identify possible disease before symptoms develop or at an earlier stage in appropriate populations. Depending on age and risk factors, breast cancer screening may involve methods such as mammography. A related guide explains when a breast ultrasound or a mammogram is used.

Diagnostic Testing

Diagnostic testing is performed when there is:

  • A breast lump
  • Abnormal imaging
  • Nipple changes
  • Suspicious findings
  • Other clinical concerns

A patient with a new breast lump should not simply wait for their next routine screening appointment. They should seek appropriate medical evaluation.

What Breast Changes Should Be Checked?

Not every breast change means cancer. However, new or persistent changes deserve medical attention. These may include:

  • A new breast lump
  • Persistent breast thickening
  • Change in breast size or shape
  • Skin dimpling
  • Skin thickening
  • Nipple inversion
  • Unusual nipple discharge
  • Persistent changes around the nipple
  • An abnormal screening result
  • Swelling around the breast or underarm

Early evaluation can determine whether the change requires imaging, biopsy or further testing.

Who May Need More Detailed Molecular or Genetic Testing?

Not every breast cancer patient requires every available molecular test. Additional testing may be considered based on:

  • Tumour characteristics
  • Cancer stage
  • Family history
  • Age at diagnosis
  • Previous cancers
  • Treatment planning
  • Recurrence
  • Suspected inherited cancer risk

A medical oncologist, breast surgeon, genetic counsellor or other appropriate specialist can determine whether additional testing is useful.

Final Takeaway

Understanding breast cancer subtypes can make a diagnosis and pathology report easier to understand.

ER, PR, HER2 and other biomarkers provide important information about the biology of a breast tumour. These results can contribute to cancer classification and help doctors determine which treatment approaches may be appropriate.

However, no single biomarker should be interpreted in isolation.

A complete breast cancer assessment may involve:

Pathology + Biomarker Testing + Molecular Testing where appropriate + Imaging + Stage + Grade + Clinical Evaluation

This combination allows the oncology team to develop a treatment strategy based on the individual patient’s cancer rather than relying on a one-size-fits-all approach.

For patients undergoing breast cancer evaluation, TruScan Diagnostics has relevant service areas including Pathology, Molecular Biology and Cancer Screening, which align with different stages of the diagnostic journey.

If you notice a new breast lump, persistent breast change or an abnormal screening result, consult a qualified healthcare professional promptly. If breast cancer has already been diagnosed, ask your treating team which pathology, biomarker and molecular tests are appropriate for your specific case.

Accurate diagnosis is the foundation of informed cancer care, and understanding the biology of a tumour can help doctors make more personalised treatment decisions.

Related Reading: Breast Ultrasound vs Mammogram

Book Breast Cancer Testing

TruScan Diagnostics offers pathology, molecular biology and the cancer screening package at our JP Nagar centres, open 24 hours. Call +91 8956 600 600 to book, or browse all diagnostic services. Confirm that the specific test your doctor has requested is currently available before visiting.

Medical Disclaimer: This article is intended for educational purposes only and should not replace professional medical advice, diagnosis, or treatment. Biomarker results, pathology reports and molecular tests need clinical interpretation. Always consult a qualified oncologist or your treating physician about your results and which tests or treatments are appropriate. Confirm the current test list and appointment availability before visiting.

TruScan Diagnostics, JP Nagar, Bengaluru

Frequently Asked Questions About Breast Cancer Subtypes

What are the molecular subtypes of breast cancer?

Commonly discussed molecular subtypes include luminal A, luminal B, HER2-enriched and basal-like/triple-negative breast cancer. Clinical classification also commonly uses hormone receptor and HER2 status.

What are ER, PR and HER2?

ER and PR are hormone receptors found on some breast cancer cells. HER2 is a protein involved in cell growth and signalling. Testing these markers helps characterise breast cancer.

What does ER-positive breast cancer mean?

It means the tumour cells contain estrogen receptors. Hormone receptor status can influence whether hormone-based treatment is appropriate.

What does PR-positive breast cancer mean?

It means progesterone receptors are detected in the tumour cells. PR is generally interpreted alongside ER and other tumour characteristics.

Why is HER2 testing done?

HER2 testing determines whether a breast tumour has HER2-related characteristics that may influence treatment decisions, including eligibility for HER2-targeted treatment.

What does HER2-positive breast cancer mean?

It means the tumour meets established criteria for HER2 positivity. HER2-positive cancers may be eligible for HER2-targeted therapies depending on the complete clinical situation.

What is triple-negative breast cancer?

Triple-negative breast cancer is generally negative for estrogen receptors, progesterone receptors and HER2.

Is triple-negative breast cancer treatable?

Yes. Treatment options are available, although the treatment strategy differs from that used for hormone receptor-positive or HER2-positive disease. The appropriate treatment depends on the individual cancer.

What is luminal A breast cancer?

Luminal A generally describes an ER-positive, HER2-negative tumour with relatively lower proliferation and often lower grade, although exact classification can vary.

What is luminal B breast cancer?

Luminal B generally refers to hormone receptor-positive cancers with characteristics associated with higher proliferation than luminal A cancers.

What is Ki-67?

Ki-67 is a marker associated with cell proliferation. It can provide information about how actively tumour cells are dividing but should not be interpreted independently.

Is molecular testing the same as genetic testing?

No. Molecular and biomarker testing examines characteristics of tumour cells, while inherited genetic testing looks for genetic variants that may be passed through families.

Can breast cancer biomarkers change?

Yes. Biomarker characteristics can sometimes differ when cancer recurs, which is why repeat testing may be considered in selected cases.

Does every breast cancer patient need molecular testing?

No. Testing should be selected according to the clinical question, tumour characteristics and treatment needs.

Where can breast cancer pathology testing be done in Bengaluru?

Patients can discuss the required investigation with their treating doctor and choose an appropriate diagnostic laboratory. TruScan Diagnostics identifies Pathology, Molecular Biology and Cancer Screening among its relevant service areas.